Dilon Technologies Introduces MarginProbe® 2 for Enhanced Breast Cancer Surgery Success

Dilon Technologies Launches MarginProbe® 2

Dilon Technologies, renowned for its innovative contributions to the healthcare sector, has officially introduced its next-generation intraoperative margin assessment device, MarginProbe® 2. This latest system received FDA approval and is now available for use in the United States, revolutionizing breast cancer surgery. With a commitment to enhancing patient care, this device is designed to provide real-time assessments during surgery, allowing for greater precision and less need for postoperative procedures.

MarginProbe® 2 builds on the success of its predecessor, the original MarginProbe®, which is already recognized for significantly reducing re-excision rates by an average of over 54%. The device was developed by Dilon's expert team based in Israel, and it integrates advanced technologies, featuring miniaturized sensors and improved detection algorithms aimed at increasing accuracy in tumor assessments. Surgeons can now receive immediate feedback, which is critical in making informed decisions during operations.

In a pivotal study conducted in the U.S., MarginProbe® 2 demonstrated a remarkable sensitivity rate of over 76% across various specimens. A significant enhancement is the option for surgeons to specifically detect either ductal carcinoma in-situ (DCIS) or invasive cancer. As a common issue in breast-conserving surgeries, DCIS accounts for a substantial proportion of re-excisions, particularly in younger patients and those over 65.

Surgeon Experiences and Testimonies

The introduction of MarginProbe® 2 has been met with enthusiasm from practicing surgeons. Dr. Vincent Reid from Mercy Hospital in Iowa shared, "Within 3-5 minutes, I have immediate results indicating whether margins are positive or negative. This capability allows me to make informed and timely decisions for my patients, maintaining my re-excision rate at an impressive 4.6%."

Similarly, Dr. Freya Schnabel from NYU Langone expressed satisfaction with the device's functionality and ease of use, saying, "MarginProbe® integrates seamlessly into the OR, adding minimal time to procedures while providing straightforward results for intraoperative assessments. The user-friendliness translates to a short learning curve, making it accessible in diverse practice settings."

Dr. Jaime Alberty from NYC Health and Hospitals System noted the advancements in the technology, remarking, "The improved sensitivity without compromising specificity makes a significant difference, predominantly concerning DCIS, which often leads to re-excisions. We are eager to utilize this technology to mitigate that issue."

The launch of MarginProbe® 2 represents a critical shift in how breast cancer surgeries can be conducted, underscoring Dilon's dedication to patient-centric technology and superior clinical outcomes. Through a robust commercial rollout, Dilon’s team will be actively promoting the device across the country, inviting hospitals and breast surgeons to learn more at their official website, www.dilon.com.

About Dilon Technologies

Founded in Newport News, Virginia, Dilon Technologies is committed to innovating in the medical device industry. Their product offerings include not just MarginProbe® but also the HEMOBLAST Bellows® and the Navigator™ 2.0 System, all aimed at improving surgical precision and patient health. Dilon remains steadfast in its mission to elevate healthcare solutions for patients worldwide.

As the medical field continues to evolve, technologies like MarginProbe® 2 are poised to redefine surgical standards and enhance the experiences and outcomes for breast cancer patients. Given the positive feedback and the strong clinical rationale behind its use, MarginProbe® 2 may soon become the gold standard in intraoperative margin assessment.